AS1404
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
BACKGROUND
Interrupting tumour blood flow and delivery of nutrients to cause tumour death is the aim of antiangiogenic and…
Purpose 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404) is a novel antitumour agent that selectively disrupts tumour…
5115 Background: DMXAA (AS1404) is a small-molecule agent that disrupts tumor vasculature. Combination of DMXAA with taxanes…
4642 The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small…
BACKGROUND
DMXAA (5,6-dimethylxanthenone-4-acetic acid; AS1404), a vascular disrupting agent currently in clinical trials…
SummaryAims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces…
Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions…
7102 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra…
5032 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra…
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from…